Harold Bernstein Sells 25,156 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CMO Harold Bernstein sold 25,156 shares of the company’s stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $40.20, for a total value of $1,011,271.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Harold Bernstein also recently made the following trade(s):

• On Monday, January 5th, Harold Bernstein sold 412 shares of Maze Therapeutics stock. The shares were sold at an average price of $40.00, for a total value of $16,480.00.
• On Friday, January 2nd, Harold Bernstein sold 4,432 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.43, for a total value of $179,185.76.
• On Monday, December 29th, Harold Bernstein sold 45,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $40.56, for a total value of $1,825,200.00.

Maze Therapeutics Stock Performance

Maze Therapeutics stock opened at $40.32 on Friday. The stock has a market capitalization of $1.94 billion and a P/E ratio of -1.93. The company’s fifty day moving average price is $37.72 and its 200 day moving average price is $25.96. Maze Therapeutics, Inc. has a 1 year low of $6.71 and a 1 year high of $43.29.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.08.

Analysts Set New Price Targets

A number of brokerages have commented on MAZE. Raymond James Financial began coverage on Maze Therapeutics in a report on Thursday, November 13th. They set an “outperform” rating and a $48.00 target price for the company. Weiss Ratings reissued a “sell (d)” rating on shares of Maze Therapeutics in a research note on Wednesday, October 8th. Guggenheim reaffirmed a “buy” rating and set a $46.00 target price on shares of Maze Therapeutics in a research note on Friday, December 19th. HC Wainwright upped their target price on shares of Maze Therapeutics from $50.00 to $60.00 and gave the stock a “buy” rating in a report on Wednesday, December 3rd. Finally, JPMorgan Chase & Co. raised their price target on shares of Maze Therapeutics from $27.00 to $37.00 and gave the stock an “overweight” rating in a research note on Monday, September 29th. Three analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $43.38.

Institutional Trading of Maze Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of MAZE. SG Americas Securities LLC raised its holdings in shares of Maze Therapeutics by 69.4% during the 4th quarter. SG Americas Securities LLC now owns 8,493 shares of the company’s stock worth $352,000 after acquiring an additional 3,478 shares during the period. JPMorgan Chase & Co. raised its stake in Maze Therapeutics by 80.7% during the third quarter. JPMorgan Chase & Co. now owns 7,890 shares of the company’s stock worth $205,000 after purchasing an additional 3,524 shares during the period. Woodline Partners LP raised its stake in Maze Therapeutics by 10.0% during the third quarter. Woodline Partners LP now owns 1,035,229 shares of the company’s stock worth $26,843,000 after purchasing an additional 94,529 shares during the period. XTX Topco Ltd purchased a new stake in shares of Maze Therapeutics in the 3rd quarter valued at approximately $697,000. Finally, Susquehanna International Group LLP grew its stake in shares of Maze Therapeutics by 53.0% in the 3rd quarter. Susquehanna International Group LLP now owns 16,165 shares of the company’s stock valued at $419,000 after buying an additional 5,598 shares during the period.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.